ArticleMolecular therapy. Oncology2026

Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.

Matthew Nazzaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.